Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
Best Standard of Care · 1 trial · 1 indication
OS is defined as the time from date of randomization to the date of death from any cause.
| Arm | Type | Description |
|---|---|---|
| Doxorubicin Transdrug (DT) at 20 mg/m2 | EXPERIMENTAL | DT will be infused over 6 hours through the intravenous (IV) route at dose of 20 mg/m2 on Day 1 and will be repeated every 4 weeks until disease progression or unacceptable toxicity |
| Doxorubicin Transdrug (DT) at 30 mg/m2 | EXPERIMENTAL | DT will be infused over 6 hours through the IV route at dose of 30 mg/m2 on Day 1 and will be repeated every 4 weeks until disease progression or unacceptable toxicity |
| Best Standard of Care | ACTIVE_COMPARATOR | Patients randomized in the control group will receive treatment according to the investigator's choice, until disease progression or unacceptable toxicity |
| Name | Type | Description |
|---|---|---|
| Doxorubicin 20 mg/m2 | DRUG | - |
| Doxorubicin 30 mg/m2 | DRUG | - |
| Best Standard of Care | DRUG | - |
Inclusion Criteria: * Male or non-pregnant, non-breast feeding female; * Aged ≥ 18 years; * Patient with: * advanced HCC (BCLC-C according to BCLC staging classification) having progressed under Sorafenib therapy or intolerant to Sorafenib, or; * intermediate HCC (BCLC-B) non eligible or non r...
Best Standard of Care is used for the treatment of hepatocellular carcinoma, a type of liver cancer. It is being studied in patients with advanced hepatocellular carcinoma. The drug is in Phase 3 clinical development and is being developed by cbdMD, Inc. (YCBD).
Best Standard of Care is being developed by cbdMD, Inc., a company traded on the stock exchange under the ticker symbol YCBD. The drug is currently in Phase 3 clinical development for the treatment of hepatocellular carcinoma, a form of liver cancer.
Best Standard of Care is in Phase 3 clinical development. It is an investigational drug being studied for the treatment of advanced hepatocellular carcinoma. The Phase 3 trial has been completed, and the drug is not yet approved by regulatory authorities.
Best Standard of Care has one completed Phase 3 clinical trial, identified as NCT01655693. This study, titled 'Efficacy and Safety Doxorubicin Transdrug Study in Patients Suffering From Advanced Hepatocellular Carcinoma,' enrolled 397 participants and was conducted in multiple countries including the United States, Austria, Belgium, Egypt, France, Germany, Hungary, Italy, Lebanon, Spain, and Turkey.
Best Standard of Care is not FDA approved. It is an investigational drug currently in Phase 3 clinical development for the treatment of advanced hepatocellular carcinoma. The Phase 3 trial has been completed, but the drug has not yet received regulatory approval.
Yes, the Phase 3 clinical trial for Best Standard of Care, NCT01655693, was randomized and active-controlled. The study enrolled 397 participants with advanced hepatocellular carcinoma and was conducted across multiple countries. The trial has been completed.